a public good project by the
Synthesis
Company
of California

© 2026

Monica Crugnola | doi.page

0 works0 citations0 h-index

Monica Crugnola

University of Parma(IT)Ospedale di Parma(IT)

Publications by Year

Research Areas

Chronic Myeloid Leukemia Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Acute Myeloid Leukemia Research, Eosinophilic Disorders and Syndromes

Most-Cited Works

→ The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients(2007)275 cited
→ Prognostic Factors for Malignant Transformation in Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma(2002)239 cited
→ Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis(2019)145 cited
→ Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission(2018)105 cited
→ Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis(2017)89 cited
→ Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP(2019)89 cited

CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival.

(2006)

→ Primary nodal marginal zone B‐cell lymphoma: clinical features and prognostic assessment of a rare disease(2006)77 cited

→ Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice(2019)76 cited

→ Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis(2015)70 cited